David Krempa sold $3.2M of ETON
Chief Business Officer at Eton Pharmaceuticals, Inc.. 100,000 shares at an average of $32.30, traded May 22, 2026, filed May 27, 2026.
Score components
- +15RoleOfficer
- +25Trade size$3.2M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-018628, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 22, 2026 | MOption exercise Common Stock | +30,591 | $3.58 | $110k | 68,046 | May 27, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock | -32,963 | $33.22 | $1.1M | 35,083 | May 27, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock | -9,315 | $33.88 | $316k | 25,768 | May 27, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock | -519 | $35.00 | $18k | 25,249 | May 27, 2026 |
| May 26, 2026 | MOption exercise Common Stock | +25,000 | $1.38 | $35k | 50,249 | May 27, 2026 |
| May 26, 2026 | MOption exercise Common Stock | +12,524 | $1.37 | $17k | 62,773 | May 27, 2026 |
| May 26, 2026 | SOpen-market sale Common Stock | -37,524 | $31.49 | $1.2M | 25,249 | May 27, 2026 |
| May 27, 2026 | MOption exercise Common Stock | +12,476 | $1.37 | $17k | 37,725 | May 27, 2026 |
| May 27, 2026 | MOption exercise Common Stock | +7,203 | $3.58 | $26k | 44,928 | May 27, 2026 |
| May 27, 2026 | SOpen-market sale Common Stock | -19,679 | $31.47 | $619k | 25,249 | May 27, 2026 |
| May 22, 2026 | MOption exercise Employee Stock Optionderivative | -30,591 | $0.00 | $0 | 125,609 | May 27, 2026 |
| May 26, 2026 | MOption exercise Employee Stock Optionderivative | -25,000 | $0.00 | $0 | 0 | May 27, 2026 |
| May 26, 2026 | MOption exercise Employee Stock Optionderivative | -12,524 | $0.00 | $0 | 12,476 | May 27, 2026 |
| May 27, 2026 | MOption exercise Employee Stock Optionderivative | -12,476 | $0.00 | $0 | 0 | May 27, 2026 |
| May 27, 2026 | MOption exercise Employee Stock Optionderivative | -7,203 | $0.00 | $0 | 118,406 | May 27, 2026 |
Related signals
Other insiders at Eton Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | ETONsell Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $229k 4,166 shares | -9% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $1.6M 25,000 shares | -40% | |
| 65Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $6.1M 100,000 shares | -9% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $4.8M 126,685 shares | -5% | |
| 45Moderate | ETONsell Eton Pharmaceuticals, Inc. | Jennifer McKie Adams director | $1.6M 50,000 shares | -100% | |
| 63Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $3.8M 120,000 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.